{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:01:38Z","timestamp":1773226898176,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.neurol.2022.11.003","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T07:13:08Z","timestamp":1670397188000},"page":"223-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod"],"prefix":"10.1016","volume":"179","author":[{"given":"A.","family":"Ciccone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mathey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Prunis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Debouverie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2022.11.003_bib0255","unstructured":"Coronavirus disease (COVID-19)\u2013World Health Organization [Internet]. [cited 2022 Jan 9]. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019.s."},{"key":"10.1016\/j.neurol.2022.11.003_bib0260","unstructured":"The different types of COVID-19 vaccines [Internet]. [cited 2022 Jan 9]. Available from: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-race-for-a-covid-19-vaccine-explained."},{"issue":"27","key":"10.1016\/j.neurol.2022.11.003_bib0265","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"issue":"10269","key":"10.1016\/j.neurol.2022.11.003_bib0270","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.003_bib0275","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.neurol.2022.11.003_bib0280","doi-asserted-by":"crossref","first-page":"577599","DOI":"10.1016\/j.jneuroim.2021.577599","article-title":"Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients","volume":"356","author":"Kelly","year":"2021","journal-title":"J Neuroimmunol."},{"issue":"6","key":"10.1016\/j.neurol.2022.11.003_bib0285","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"10023","key":"10.1016\/j.neurol.2022.11.003_bib0290","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet."},{"issue":"5","key":"10.1016\/j.neurol.2022.11.003_bib0295","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.neurol.2022.11.003_bib0300","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.neurol.2022.11.003_bib0305","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clim.2011.05.005","article-title":"Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy","volume":"142","author":"Ingwersen","year":"2012","journal-title":"Clin Immunol."},{"issue":"19","key":"10.1016\/j.neurol.2022.11.003_bib0310","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology."},{"issue":"14","key":"10.1016\/j.neurol.2022.11.003_bib0315","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1177\/1352458520971817","article-title":"COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments","volume":"27","author":"Laroni","year":"2021","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"1","key":"10.1016\/j.neurol.2022.11.003_bib0320","doi-asserted-by":"crossref","first-page":"e1105","DOI":"10.1212\/NXI.0000000000001105","article-title":"COVID-19 severity in multiple sclerosis: putting data into context","volume":"9","author":"Sormani","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflammation."},{"issue":"9","key":"10.1016\/j.neurol.2022.11.003_bib0325","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-020-00756-y","article-title":"Multiple sclerosis disease-modifying therapy and the COVID-19 pandemic: implications on the risk of infection and future vaccination","volume":"34","author":"Zheng","year":"2020","journal-title":"CNS Drugs."},{"issue":"4","key":"10.1016\/j.neurol.2022.11.003_bib0330","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1352458513500551","article-title":"Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy","volume":"20","author":"Francis","year":"2014","journal-title":"Mult Scler J."},{"issue":"4","key":"10.1016\/j.neurol.2022.11.003_bib0335","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann Neurol."},{"issue":"5","key":"10.1016\/j.neurol.2022.11.003_bib0340","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation."},{"issue":"7","key":"10.1016\/j.neurol.2022.11.003_bib0345","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.neurol.2022.11.003_bib0350","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1177\/1352458520931785","article-title":"Keeping standards of multiple sclerosis care through the COVID-19 pandemic","volume":"26","author":"Sastre-Garriga","year":"2020","journal-title":"Mult Scler J."},{"key":"10.1016\/j.neurol.2022.11.003_bib0355","doi-asserted-by":"crossref","first-page":"102439","DOI":"10.1016\/j.msard.2020.102439","article-title":"Effects of MS disease-modifying therapies on responses to vaccinations: a review","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult Scler Relat Disord."},{"issue":"9","key":"10.1016\/j.neurol.2022.11.003_bib0360","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","article-title":"Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.neurol.2022.11.003_bib0365","unstructured":"Number of people with MS | Atlas of MS [Internet]. [cited 2022 Jan 9]. Available from: https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms."},{"key":"10.1016\/j.neurol.2022.11.003_bib0370","series-title":"The coronavirus and MS\u00a0\u2013\u00a0updated global advice [Internet]","year":"2020"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.003_bib0375","doi-asserted-by":"crossref","first-page":"e1055","DOI":"10.1212\/NXI.0000000000001055","article-title":"Impact of disease-modifying treatments of multiple sclerosis on anti-SARS-CoV-2 antibodies: an observational study","volume":"8","author":"Bigaut","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflammation."},{"issue":"51","key":"10.1016\/j.neurol.2022.11.003_bib0380","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1016\/j.vaccine.2021.10.068","article-title":"Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments","volume":"39","author":"Wagner","year":"2021","journal-title":"Vaccine."},{"key":"10.1016\/j.neurol.2022.11.003_bib0385","doi-asserted-by":"crossref","first-page":"104102","DOI":"10.1016\/j.ebiom.2022.104102","article-title":"Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis","volume":"81","author":"Wu","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.neurol.2022.11.003_bib0390","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.neurol.2022.11.003_bib0395","first-page":"e69375","article-title":"BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralisation of P.1 Brazilian variant. Rochester, NY","volume":"10","author":"Parry","year":"2021","journal-title":"Soc Sci Res Network"},{"issue":"12","key":"10.1016\/j.neurol.2022.11.003_bib0400","doi-asserted-by":"crossref","first-page":"2100329","DOI":"10.2807\/1560-7917.ES.2021.26.12.2100329","article-title":"Robust antibody responses in 70\u201380-year-olds 3 weeks after the first or second doses of Pfizer\/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021","volume":"26","author":"Subbarao","year":"2021","journal-title":"Eurosurveillance."},{"issue":"9","key":"10.1016\/j.neurol.2022.11.003_bib0405","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41564-021-00947-3","article-title":"Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom","volume":"6","author":"Wei","year":"2021","journal-title":"Nat Microbiol."},{"key":"10.1016\/j.neurol.2022.11.003_bib0410","series-title":"REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England [Internet]","author":"Ward","year":"2021"},{"issue":"6","key":"10.1016\/j.neurol.2022.11.003_bib0415","first-page":"2100096","article-title":"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021","volume":"26","author":"Jabal","year":"2021","journal-title":"Eurosurveillance."},{"key":"10.1016\/j.neurol.2022.11.003_bib0420","series-title":"Age-dependent immune response to the Biontech\/Pfizer BNT162b2 COVID-19 vaccination [Internet]","author":"M\u00fcller","year":"2021"},{"key":"10.1016\/j.neurol.2022.11.003_bib0425","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg Health Eur."},{"issue":"10","key":"10.1016\/j.neurol.2022.11.003_bib0430","doi-asserted-by":"crossref","first-page":"1516e7","DOI":"10.1016\/j.cmi.2021.05.041","article-title":"Quantitative SARS-CoV-2 anti-spike responses to Pfizer\u2013BioNTech and Oxford\u2013AstraZeneca vaccines by previous infection status","volume":"27","author":"Eyre","year":"2021","journal-title":"Clin Microbiol Infect."},{"issue":"7","key":"10.1016\/j.neurol.2022.11.003_bib0435","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41577-020-0348-8","article-title":"Considering how biological sex impacts immune responses and COVID-19 outcomes","volume":"20","author":"Scully","year":"2020","journal-title":"Nat Rev Immunol."},{"issue":"10","key":"10.1016\/j.neurol.2022.11.003_bib0440","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol."},{"issue":"8","key":"10.1016\/j.neurol.2022.11.003_bib0445","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-0378-2","article-title":"Sex differences in immune responses in COVID-19","volume":"20","author":"Park","year":"2020","journal-title":"Nat Rev Immunol."},{"issue":"2","key":"10.1016\/j.neurol.2022.11.003_bib0450","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex differences in vaccine-induced humoral immunity","volume":"41","author":"Fischinger","year":"2019","journal-title":"Semin Immunopathol."},{"issue":"5","key":"10.1016\/j.neurol.2022.11.003_bib0455","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1007\/s00415-022-11030-0","article-title":"Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod","volume":"269","author":"Achiron","year":"2022","journal-title":"J Neurol."},{"key":"10.1016\/j.neurol.2022.11.003_bib0460","article-title":"CD19+ B cell numbers predict the increase of anti-SARS-CoV-2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis [Internet]","author":"Schiavetti","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.neurol.2022.11.003_bib0465","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.003_bib0470","first-page":"39","article-title":"Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience","volume":"269","author":"S G","year":"2021","journal-title":"J Neurol."},{"issue":"1","key":"10.1016\/j.neurol.2022.11.003_bib0475","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ana.26251","article-title":"COVID-19 vaccine response in people with multiple sclerosis","volume":"91","author":"Tallantyre","year":"2022","journal-title":"Ann Neurol."},{"key":"10.1016\/j.neurol.2022.11.003_bib0480","first-page":"e541","article-title":"Humoral- and T-cell \u2013 specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies","volume":"98(5)","author":"Tortorella","year":"2021","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.neurol.2022.11.003_bib0485","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0b013e31829a3311","article-title":"T-cell response against varicella-zoster virus in fingolimod-treated MS patients","volume":"81","author":"Ricklin","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.neurol.2022.11.003_bib0490","doi-asserted-by":"crossref","first-page":"101963","DOI":"10.1016\/j.msard.2020.101963","article-title":"Is antibody titer useful to verify the immunization after VZV vaccine in MS patients treated with Fingolimod? A case series","volume":"40","author":"Signoriello","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.neurol.2022.11.003_bib0495","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1007\/s00415-022-11296-4","article-title":"Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod","volume":"269(12)","author":"Capuano","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2022.11.003_bib0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103724","article-title":"Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod","volume":"60","author":"Capuano","year":"2022","journal-title":"Mult Scler Relat Disord"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722008244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722008244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:46:19Z","timestamp":1758519979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378722008244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0035378722008244"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.11.003","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}